• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Alkermes plc - Ordinary Shares (NQ:ALKS)

    36.15 -0.10 (-0.29%)
    Streaming Delayed Price Updated: 9:49 AM EDT, May 6, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Alkermes plc - Ordinary Shares

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    12 13 Next >
    News headline image
    Alkermes (ALKS) Q1 2026 Earnings Transcript ↗
    Alkermes (ALKS) Q1 2026 Earnings Transcript 
    Via The Motley Fool
    Alkermes plc (NASDAQ:ALKS) Reports Mixed Q1 Results, Beats Revenue Forecasts but Posts Wider Than Expected Loss ↗
    Via Chartmill
    News headline image
    Alkermes plc Reports First Quarter 2026 Financial Results
    From Alkermes plc
    Via Business Wire
    Alkermes Plc (NASDAQ:ALKS) Shows Strong Technical Setup with High Breakout Potential ↗
    Via Chartmill
    Alkermes PLC (NASDAQ:ALKS) Reports Strong Q4 Earnings Beat Amid Muted Market Reaction ↗
    Via Chartmill
    Topics Earnings
    Race For Avadel Heats Up: Alkermes Raises Offer To Secure $2.37B Deal After Lundbeck Challenge ↗
    Via Stocktwits
    News headline image
    Alkermes to Report First Quarter Financial Results on May 5, 2026
    From Alkermes plc
    Via Business Wire
    News headline image
    Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting
    From Alkermes plc
    Via Business Wire
    News headline image
    Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry
    From Alkermes plc
    Via Business Wire
    News headline image
    Lilly’s $7.8 Billion Centessa Bet: Inside the Race to Dominate the Sleep Market’s ‘Orexin Gold Rush’
    On March 31, 2026, Eli Lilly and Company (NYSE:LLY) sent shockwaves through the biotechnology sector by announcing a definitive agreement to acquire Centessa Pharmaceuticals (Nasdaq:CNTA) for a total... 
    Via MarketMinute
    News headline image
    Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2
    From Alkermes plc
    Via Business Wire
    News headline image
    The Orexin Gold Rush: Deep Dive into Eli Lilly’s $7.8 Billion Acquisition of Centessa Pharmaceuticals
    Today, March 31, 2026, the biotechnology landscape has been fundamentally reshaped. Eli Lilly and Company (NYSE: LLY) has officially announced a definitive agreement to acquire Centessa Pharmaceuticals... 
    Via Finterra
    Topics Economy Initial Public Offering Intellectual Property
    News headline image
    Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program
    From Alkermes plc
    Via Business Wire
    News headline image
    Alkermes to Present at the Stifel 2026 Virtual CNS Forum
    From Alkermes plc
    Via Business Wire
    News headline image
    Alkermes (ALKS) Q4 2025 Earnings Call Transcript ↗
    Alkermes (ALKS) Q4 2025 Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings
    News headline image
    Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026
    From Alkermes plc
    Via Business Wire
    News headline image
    Alkermes plc Announces CEO Succession Plan
    From Alkermes plc
    Via Business Wire
    News headline image
    Alkermes to Present at the TD Cowen 46th Annual Health Care Conference
    From Alkermes plc
    Via Business Wire
    News headline image
    From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer ↗
    Agios Pharmaceuticals develops therapies for rare blood disorders, anchored by its PYRUKYND franchise and early-stage clinical programs. 
    Via The Motley Fool
    News headline image
    Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake ↗
    Viridian Therapeutics develops monoclonal antibody therapies targeting rare diseases, with a focus on thyroid eye disease treatments. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million ↗
    Spyre Therapeutics develops preclinical monoclonal antibody therapies targeting inflammatory bowel disease and related conditions. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50% ↗
    Centessa Pharmaceuticals develops clinical-stage therapies for rare and serious diseases, leveraging a portfolio approach in biopharma. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% ↗
    Nuvalent develops targeted cancer therapies, advancing clinical candidates for patients with limited treatment options in oncology. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market
    From Alkermes plc
    Via Business Wire
    News headline image
    Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026
    From Alkermes plc
    Via Business Wire
    News headline image
    Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1
    From Alkermes plc
    Via Business Wire
    News headline image
    Alkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference
    From Alkermes plc
    Via Business Wire
    News headline image
    Alkermes to Participate in Two Upcoming Investor Conferences
    From Alkermes plc
    Via Business Wire
    News headline image
    Lundbeck's Higher Buyout Proposal Challenges Alkermes' Pending $2 Billion Avadel Deal ↗
    Avadel reviews Lundbeck's unsolicited $23 offer while maintaining its agreement with Alkermes as its board evaluates whether the new proposal could be superior. 
    Via Benzinga
    News headline image
    Avadel Surges 20% On Lundbeck's Surprise Alkermes-Topping Bid ↗
    A new bidding war could kick off in biotech with Avadel Pharmaceuticals at the center. 
    Via Investor's Business Daily
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    12 13 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.